Dr Reddy's signs strategic deal with Gland Pharma
Hyderabad-based Dr Reddy's Laboratories Ltd
on Wednesday said that it had entered into a strategic collaboration with Gland Pharma,
a globally recognized developer and manufacturer of sterile dosage forms, to
market and distribute a diverse portfolio of eight injectable Abbreviated New Drug
Applications (ANDAs) in the US market.
The portfolio is a mix of filed ANDAs pending
approval by the US Food and Drug Administration (USFDA) and ANDAs that will be
filed imminently, and comprised of generic injectables administered in
hospitals and clinics in the US. The combined sale of branded and generic
versions of the products in the US is nearly $1 billion for the most recent 12
months ending August 2016, according to IMS Health.
"Dr
Reddy's Laboratories has a strong track record in developing, marketing and
distributing generic injectables in the US. Our strengths, combined with
Gland's track record of manufacturing and operational excellence, will help
bring affordable medications within reach of patients and complement our
specialty injectables offering in the short-to-medium term," said Alok
Sonig, Executive Vice President and Head of North America, Dr Reddy's. Srinivas
Sadu, Chief Operating Officer, Gland Pharma, hoped that the company’s
partnership with Dr Reddy's would continue to grow.
Comments
Post a Comment